Pfizer Inc.(PFE)NASDAQ
Stock Overview & Analysis
Pfizer Inc. (PFE) quick overview 2026-02-20
- The stock is currently trading at $26.65, experiencing a price strength within a larger uptrend—trading above its 50-day average while holding above the 200-day.
- Analysts appear optimistic, with a 1-year price target of $28.71 (7.7% upside).
- Volatility is elevated (23.09% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (-1.20% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $202.86B
P/E Ratio
Forward P/E: 9.44
Revenue Growth
Year over Year
Analyst Target
+7.7% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 46.97)
- Fundamentals say: Challenging (declining revenue trends)
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $61.94B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
Trading Range
Over the past year, the stock traded between $20.92 and $27.94—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 23.09% annualized volatility and β=0.44, the stock exhibits low sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
Is Pfizer Stock an Underrated Healthcare Investment Play?
Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Barclays launches U.S. biopharma coverage with four preferred picks
Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.
Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial
Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer. Management noted that the combination showed significant PFS improvement and better overall […]
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
New products are already generating growth.
Pfizer Oncology And Rare Disease Milestones Shape Long Term Growth Prospects
Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in previously untreated metastatic colorectal cancer patients with the BRAF V600E mutation in a Phase 3 trial. The US FDA granted Priority Review for a HYMPAVZI filing that seeks to expand its use to hemophilia A or B patients, including pediatric populations. For you as an investor, these updates sit at the heart of what Pfizer is trying to build beyond its established...
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Where is Pfizer Inc. (PFE) Headed?
Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority […]
Top High-Yield Stocks to Double Up on Right Now
If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.
2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $26.65. The RSI (14-day) is at 47.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.71 implies 7.7% upside from current levels. Volatility is moderate at 23.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 19.63, which is in line with broader market averages. The forward P/E is 9.44, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 3.77, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.64. Price-to-Sales is 2.42. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering PFE, the consensus price target is $28.71. This represents a 7.7% upside from the current price of $26.65. The range spans from a low target of $25.00 to a high target of $35.46, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.45%. The annualized dividend rate is $1.72 per share. The payout ratio is 126.5%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-01-23.
Key risks for Pfizer Inc. (PFE) investors include: 1. Declining revenue (-1.2% YoY), indicating potential business headwinds. 2. Unsustainable dividend payout ratio (126%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $61.94B. The debt-to-equity ratio is 66.53, which is moderate and generally manageable for most companies. The company holds $14.99B in cash and equivalents.